- Home
- TNYA vs ALXO Comparison
TNYA vs ALXO Comparison
Compare TNYA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- ALXO
- Stock Information
- Founded
- TNYA 2016
- ALXO 2015
- Country
- TNYA United States
- ALXO United States
- Employees
- TNYA N/A
- ALXO N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- ALXO Health Care
- Exchange
- TNYA Nasdaq
- ALXO Nasdaq
- Market Cap
- TNYA 74.7M
- ALXO 76.5M
- IPO Year
- TNYA 2021
- ALXO 2020
- Fundamental
- Price
- TNYA $1.11
- ALXO $1.12
- Analyst Decision
- TNYA Strong Buy
- ALXO Buy
- Analyst Count
- TNYA 5
- ALXO 6
- Target Price
- TNYA $17.50
- ALXO $6.64
- AVG Volume (30 Days)
- TNYA 1.9M
- ALXO 769.2K
- Earning Date
- TNYA 03-17-2025
- ALXO 03-06-2025
- Dividend Yield
- TNYA N/A
- ALXO N/A
- EPS Growth
- TNYA N/A
- ALXO N/A
- EPS
- TNYA N/A
- ALXO N/A
- Revenue
- TNYA N/A
- ALXO N/A
- Revenue This Year
- TNYA N/A
- ALXO N/A
- Revenue Next Year
- TNYA N/A
- ALXO N/A
- P/E Ratio
- TNYA N/A
- ALXO N/A
- Revenue Growth
- TNYA N/A
- ALXO N/A
- 52 Week Low
- TNYA $0.86
- ALXO $0.96
- 52 Week High
- TNYA $7.01
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- TNYA 44.41
- ALXO 38.53
- Support Level
- TNYA $1.43
- ALXO $1.00
- Resistance Level
- TNYA $1.12
- ALXO $1.22
- Average True Range (ATR)
- TNYA 0.10
- ALXO 0.09
- MACD
- TNYA 0.05
- ALXO 0.00
- Stochastic Oscillator
- TNYA 65.70
- ALXO 35.12
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.